search
Back to results

Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders (GARET2019)

Primary Purpose

Fear of Spiders

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
AR app
Sponsored by
Prof. Dominique de Quervain, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Fear of Spiders

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Fear of spiders
  • BAT score before exposure between 1-8
  • Physically healthy
  • Fluent in German

Exclusion Criteria:

  • BDI-II sumscore >=20 and/or item 9 >=1
  • Concurrent psychotherapy or pharmacotherapy
  • Previous exposure-based therapy for spider phobia
  • Parallel participation in another study
  • Chronic medication intake (except oral contraceptives)
  • Medication intake before visits (less than 24h)
  • Alcohol intake before visits (less than 12 h)
  • Cannabis or other psychoactive substances (including benzodiazepines) intake before visits (less than 5 days)
  • For women: Current pregnancy

Sites / Locations

  • University of Basel

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exposure

Control

Arm Description

The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.

The control group will not receive any active treatment (untreated comparison group).

Outcomes

Primary Outcome Measures

Subjective fear (SUDS) in the in vivo BAT
During the BAT participants will be placed in front of a closed room with a spider in it and will be asked to open the door and approach a living house spider measuring about 5 cm, which will be placed in a sealed transparent plastic container on a table at the far end of the room. The participant will be requested to approach the spider and if possible, to touch the container, to remove the lid, insert a hand, and try to pick up and hold the spider for at least 20 s. Pre-defined scores ranging from 0 = refuses to enter the test room to 12 = holds the spider for at least 20 s will be given when the BAT was completed after 3 minutes or terminated by the participant. SUDS for fear and disgust will be taken during the BAT on the same score as on day one, ranging from 0 = no fear to 10 = maximum fear.

Secondary Outcome Measures

Performance Behavioural Approach Test (BAT) in vivo
See primary outcome for a detailed description.
Subjective disgust (SUDS) in the in vivo BAT
See primary outcome for a detailed description.
Fear of spiders Questionnaire (FSQ)
The FSQ measures avoidance behavior as well as fear of harm and consists of 18 spider relevant situations. Participants evaluate their relationship to spiders on a 7-point Likert-type scale (0 = not at all true to 6 = absolutely true, range 0 - 108) (Szymanski and O'Donohue, 1995)
Spider Beliefs Questionnaire (SBQ)
The SBQ assesses specifically spider-related catastrophic cognitions that will be challenged within the exposure sessions and consists of 48 possible thoughts and beliefs in spider situations. Participants evaluate whether they are convinced these beliefs are true while being in a spider situation with a percentage (0 = not at all convinced to 100 = firmly convinced) (Arntz et al. 1993)
Clinical rating for specific phobia (DSM-V)
Fear of spiders will be re-assessed by the section for specific phobia (animal type: spider) of the structured diagnostic interview for mental disorders for DSM-V (DIPS, Schneider & Margraf, 2017)
Self-reported change in fear of spiders
For the self-reported change of fear of spiders participants were asked to self-rate their subjective change in fear of spiders on a single visual analogue scale in a range of 0 to 100 (0 = a lot worse, 50 = no change and 100 = a lot better).

Full Information

First Posted
November 11, 2019
Last Updated
December 19, 2019
Sponsor
Prof. Dominique de Quervain, MD
Collaborators
Swiss National Science Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04162509
Brief Title
Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders
Acronym
GARET2019
Official Title
Randomized Controlled Trial on the Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
October 7, 2019 (Actual)
Primary Completion Date
December 4, 2019 (Actual)
Study Completion Date
December 4, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Dominique de Quervain, MD
Collaborators
Swiss National Science Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Investigation of the efficacy of a gamified augmented reality exposure app in individual with fear of spiders.
Detailed Description
The study will be conducted as a randomized controlled between subject trial. The study consists of two visits and a home training for one group. 60 participants between 18 and 40 years with clinical or subclinical fear of spiders will take part in the study. All assessments of outcome will be conducted on one visit for each participant, including an in vivo BAT. The experimental group will participate in a home training with the app, spanning over two weeks (6x30-minutes sessions), whereas the control group will not receive any treatment (untreated comparison group). Six weeks after the first visit all participants undergo the assessments of outcome, including a second in vivo BAT. The BAT will take place 4 weeks after completion of the home training. This design allows a direct comparison and therefore an estimation of the efficacy of the gamified AR exposure therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fear of Spiders

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled single-blind study design
Masking
Outcomes Assessor
Masking Description
Participants will be randomly (matched by clinical relevance of fear of spiders and sex) allocated to treatment groups (experimental group, control group). The experimenter evaluating the primary outcome will be blinded (unaware of group assignment of participants, single-blind).
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exposure
Arm Type
Experimental
Arm Description
The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.
Arm Title
Control
Arm Type
No Intervention
Arm Description
The control group will not receive any active treatment (untreated comparison group).
Intervention Type
Other
Intervention Name(s)
AR app
Intervention Description
Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
Primary Outcome Measure Information:
Title
Subjective fear (SUDS) in the in vivo BAT
Description
During the BAT participants will be placed in front of a closed room with a spider in it and will be asked to open the door and approach a living house spider measuring about 5 cm, which will be placed in a sealed transparent plastic container on a table at the far end of the room. The participant will be requested to approach the spider and if possible, to touch the container, to remove the lid, insert a hand, and try to pick up and hold the spider for at least 20 s. Pre-defined scores ranging from 0 = refuses to enter the test room to 12 = holds the spider for at least 20 s will be given when the BAT was completed after 3 minutes or terminated by the participant. SUDS for fear and disgust will be taken during the BAT on the same score as on day one, ranging from 0 = no fear to 10 = maximum fear.
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Secondary Outcome Measure Information:
Title
Performance Behavioural Approach Test (BAT) in vivo
Description
See primary outcome for a detailed description.
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
Subjective disgust (SUDS) in the in vivo BAT
Description
See primary outcome for a detailed description.
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
Fear of spiders Questionnaire (FSQ)
Description
The FSQ measures avoidance behavior as well as fear of harm and consists of 18 spider relevant situations. Participants evaluate their relationship to spiders on a 7-point Likert-type scale (0 = not at all true to 6 = absolutely true, range 0 - 108) (Szymanski and O'Donohue, 1995)
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
Spider Beliefs Questionnaire (SBQ)
Description
The SBQ assesses specifically spider-related catastrophic cognitions that will be challenged within the exposure sessions and consists of 48 possible thoughts and beliefs in spider situations. Participants evaluate whether they are convinced these beliefs are true while being in a spider situation with a percentage (0 = not at all convinced to 100 = firmly convinced) (Arntz et al. 1993)
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
Clinical rating for specific phobia (DSM-V)
Description
Fear of spiders will be re-assessed by the section for specific phobia (animal type: spider) of the structured diagnostic interview for mental disorders for DSM-V (DIPS, Schneider & Margraf, 2017)
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
Self-reported change in fear of spiders
Description
For the self-reported change of fear of spiders participants were asked to self-rate their subjective change in fear of spiders on a single visual analogue scale in a range of 0 to 100 (0 = a lot worse, 50 = no change and 100 = a lot better).
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Other Pre-specified Outcome Measures:
Title
Self-reported change in disgust of spiders
Description
For the self-reported change of disgust of spiders participants were asked to self-rate their subjective change in disgust of spiders on a single visual analogue scale in a range of 0 to 100 (0 = a lot worse, 50 = no change and 100 = a lot better).
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
AR exposure app acceptability and usability scale
Description
The AR exposure app acceptability and usability scale consists of 11 items that assess the overall acceptability and usability (e.g. design, functionality) of the AR app for the experimental group. The items were solely composed for our study purposes. The first 9 items will be assessed through a 11-point scale, item 10 and 11 have an open answer format. Higher scores indicate higher acceptability and usability.
Time Frame
6 weeks after day one (4 weeks after completion of home training)
Title
Credibility/Expactancy scale
Description
The experimental groups therapy expectations regarding the successful treatment of their fear will be measured by an adapted credibility/expectancy for improvement scales with 5 statements. Participants rate their expectancy on a 11-point Likert-type scale (0 = not at all, 10 = absolutely, range 0 - 10) (Borkovec & Nau, 1972)
Time Frame
On study day one

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Fear of spiders BAT score before exposure between 1-8 Physically healthy Fluent in German Exclusion Criteria: BDI-II sumscore >=20 and/or item 9 >=1 Concurrent psychotherapy or pharmacotherapy Previous exposure-based therapy for spider phobia Parallel participation in another study Chronic medication intake (except oral contraceptives) Medication intake before visits (less than 24h) Alcohol intake before visits (less than 12 h) Cannabis or other psychoactive substances (including benzodiazepines) intake before visits (less than 5 days) For women: Current pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique de Quervain, Prof.
Organizational Affiliation
University of Basel
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Basel
City
Basel
State/Province
BS
ZIP/Postal Code
4055
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders

We'll reach out to this number within 24 hrs